DOCSLIB.ORG

Curriculum Vitae July 2015

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Curriculum Vitae July 2015 CURRICULUM VITAE JULY 2015 G. RICHARD CURL, M.D., F.A.C.S., RVT Office Address: BEVSA 100 High Street Suite A-2 Buffalo, NY 14203 Phone: (716) 859-3301 EDUCATION: Fellowship Training: 1983 - 1984 Vascular Surgery, Veteran’s Administration Medical Ctr. Boston, Massachusetts Post Graduate Training: 1977 - 1983 Internship and Residency, General Surgery, Georgetown University Hospital, Washington, DC Undergraduate Training: 1973 - 1977 M.D., Tufts University Medical School, Boston, Massachusetts 1969 - 1973 University of Pennsylvania, Philadelphia, Pennnsylvania B.A. - Biology Specialty Training Course: 1997 Endovascular Training Symposium for Vascular Surgeons, SUNY Health Science Center at Brooklyn. New York, NY. January 26 – 31, 1997 Endovascular Surgery Workshop. Society of Vascular Surgery – North American Chapter, International Society for Cardiovascular Surgery. 1997 Joint Annual Meeting. Boston, MA – June 1 – 5, 1997. 1 Specialty Training Courses (cont.) 2000 Meadox Aneurex Endovascular Graft Certification Cleveland, Ohio, June 14 – 16. Guidant Ancure Endovascular Graft Certification Philadelphia, PA, August 21 – 22. Certification and Licensure: 10/27/98 – Present New York State License: 176666-1 12/12/84 – Present DEA # AC2971883 1984 – 1985 Diplomat, American Board of Surgery, #30099 1993 – 2005 Diplomat, American Board of Surgery (Recertification) 1988 – 1998 American Board of General Vascular Surgery #734 1996 – 2008 American Board of General Vascular Surgery (Recertification) 1994 Registered Vascular Technologist (RVT) EMPLOYMENT HISTORY 2007 – Present Vascular Surgeon, Buffalo Endovascular and Vascular Surgical Associates, PLLC – Chairman. Buffalo, New York. 1998 – 2007 Vascular Surgeon, Buffalo Medical Group, Buffalo, New York. 1998 – 2004 Director of Vascular Surgery, Kaleida Health Systems, Buffalo, New York. 2000 – 2002 Director, Noninvasive Vascular Laboratory, Millard Fillmore Suburban Hospital, Williamsville, NY. 1997 – 1998 Acting Chief, Division of Vascular Surgery, State University of New York at Buffalo, School of Medicine and Biomedical Sciences, Buffalo, NY. 2 EMPLOYMENT HISTORY (cont) 1994 – Present Clinical Professor of Surgery, State University of New York at Buffalo, School of Medicine and Biomedical Sciences, Buffalo, New York. 1995 – Present Consultant in Vascular Surgery, Children’s Hospital of Buffalo, Buffalo, New York. 1995 – Present Consultant in Vascular Surgery, Roswell Park Cancer Institute, Buffalo, New York. 1995 – 2004 Attending in Vascular Surgery, Kenmore Mercy Hospital, Kenmore, New York. 1992 – Present Attending in Vascular Surgery, Buffalo General Hospital, Buffalo, New York. 1988 – Present Attending Surgeon, Buffalo General Hospital, Buffalo, New York. 1992 – Present Attending in Vascular Surgery, Millard Fillmore Hospital, Buffalo, New York. 1992 – 1998 Chief, Vascular Laboratory, Buffalo General Hospital, Buffalo, New York. 1988 – 1998 Attending Surgeon, Erie County Medical Center, Buffalo, New York. 1988 – 1998 Attending Surgeon, Veteran’s Administration Medical Center, Buffalo, New York. 1988 – 1996 Assistant Professor of Surgery, State University of New York at Buffalo, School of Medicine and Biomedical Sciences, Buffalo, New York. 1986 – 1988 Assistant Professor of Surgery, UMDNJ New Jersey Medical School. 1986 – 1988 Chief, Vascular Surgery Section, East Orange Veteran’s Administration Medical Center, East Orange, New Jersey. 3 1986 – 1988 Staff Surgeon, East Orange Veteran’s Administration Medical Center, East Orange, New Jersey. 1984 – 1985 Associate Investigator, Boston Veteran’s Administration Medical Center, Boston, Massachusetts. PROFESSIONAL MEMBERSHIPS AND ACTIVITIES May 9, 1987 – Present Member, Eastern Vascular Society Oct. 27, 1988 – Present Fellow, American College of Surgeons 1987 - Present Member, American Academy of Surgeons May 3, 1990 – Present Member, Western New York Vascular Society June 5, 1990 – Present Member, International Society of Cardiovascular Surgery Oct. 14,1992- Present Member, Buffalo Surgical Society Feb. 21,1995-Present Member, International Society of Endovascular Specialists COMMUNITY, UNIVERSITY, FACULTY, DEPARTMENT SERVICE National Committees: 1997 – 1998 President, Western New York Vascular Society 1996 – 1997 Vice President, Western New York Vascular Society 1995 – 1996 Chairman, Issues Committee, Eastern Vascular Society University Service: 1995 – 1998 Institutional Review Board, Medical/Dental Staff Committee, Buffalo General Hospital. 1992 – 1998 Coordinator, Buffalo General Hospital Division III Third-Year Surgery rotation weekly study conference. 1994 – 1998 Co-Director, Division III Service, Buffalo General Hospital 4 University Service (cont) 1991 – 1998 Coordinator, City-Wide Vascular Grand Rounds Weekly topic conference. 1995 – 1996 Curriculum Committee, State University of New York at Buffalo. 1995 – 1996 Faculty Council, State University of New York at Buffalo. 1989 – 1993 Bimonthly lecture on arterial disease for Surgery 700 course. 1989 – 1993 Coordinator, Buffalo Veteran’s Administration Medical Center, Fourth-year surgery rotation weekly study conference. RESEARCH ACTIVITIES GRANT SUPPORT Completed Principal Investigator, “A Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vasoprost (Alprostadil) in the Treatment of Patients with Severe Intermittent Claudication Due to Peripheral Arterial Occlusion Disease (PAOD)”. Protocol KU-610-004/F-9014, Quintiles, Inc., Cambridge, MA. Completed Principal Investigator, “A Phase III, Controlled, Multi-Center Randomized, Parallel-Group, Single-Blind Study to Compare the Safety and Hemostatic Efficacy of the Fibrin Sealant, Beriplast® P, with Standard Care of Thrombin-Soaked Gelfoam® in the Treatment of Bleeding Anastomosis Site in Surgical Patients Receiving PTFE Bypass Grafts to the Common Femoral Artery. Protocol B191.201.3/3/2-3001, Centeon LLC, (now Aventis-Behring), King of Prussia, PA. Completed Principal Investigator, “A Randomized, Double-Blind Placebo and Active-Controlled, Dose Response, Efficacy and Safety Study of Iloprost Clathrate Extended-Release Capsules (Iloprost) in Patients with Peripheral Arterial Occlusive Disease (PAOD) (Fontaine Stage II). Protocol 107-06, Berlex Laboratories, Montville, New Jersey. 5 Completed Principal Investigator, Post Market Study for Trivascular-Ovation Endograft, 2014-2015. GRANT SUPPORT (cont.) Completed Principal Investigator, “A Multi-Center, Double-Blind, Parallel Group Efficacy and Safety Comparison of Ifetroban And Placebo in Patients with Venous Leg Ulcers”. Protocol CV 139-001, Bristol-Myers Squibb Pharmaceutical Research Institute- Conva Tech, Princeton, New Jersey. Completed Intraarterial Urokinase versus surgery for the treatment of acute lower extremity ischemia, begun April, 1994. $23,000.00. Completed Investigator, “Platelet derived growth factor and wound healing”. Buffalo Veteran’s Administration Medical Center, Buffalo, New York, $10,000.00. Completed Co-Investigator, “Iloprost in the healing of arterial ulcers”. Buffalo Veteran’s Administration Medical Center, Buffalo, New York. Completed Co-Investigator, “Intraoperative Intraarterial Urokinase study”. Buffalo Veteran’s Administration Medical Center, Buffalo, New York, $12,000.00. Completed Veteran’s Administrative Cooperative Study Number 309, Buffalo Veteran’s Administration Medical Center, Buffalo, New York. Completed Veteran’s Administrative Cooperative Study Number 362, Buffalo Veteran’s Administration Medical Center, Buffalo, New York. 1987 – 1990 Enhancement of endothelial seeding of prosthetic grafts. Buffalo Veteran’s Administration Medical Center, Buffalo, New York. 1985 – 1987 Veteran’s Administration Regional Advisory Group Grant, $25,000/year. 1984 – 1985 Veteran’s Administration Career Development Award, $34,000/year. 6 PUBLICATIONS Books/Chapters 1. Curl, GR, Ricotta, JJ: Proximal para-anastomotic aortic aneurysms in critical Problems in vascular surgery. Veith, F (ed), Quality Medical Publishing, Vol. 5, 1993. 2. Curl, GR, Faggioli, GL, Ricotta, JJ: Total excision and extra-anatomic bypass for infected intrarenal aortic grafts in symposium on vascular graft infection. Veith, FJ (ed), Quality Medical Publishing. 3. Curl, GR, Ricotta, JJ: Carotid artery string sign: Differential diagnosis and management. Veith, FJ (ed), Quality Medical Publishing. 4. Curl, GR, Ricotta, JJ: Total prosthetic graft excision and extra-anatomic Bypass. Calligaro, KD, Veith, FJ (eds), Quality Medical Publishing, P 82 -94, 1994. 5. Ramanthan, A, Curl, RG, Harris, L, Two-stage Brachiolbasilic Arteriovenous Fistula for Chronic Haemodialysis Access. ANZ J Surg.2008; March 78 (3): 215 author reply 216. 6. Maru, S, Doslouglu, H, Dryjski, M, Cherr, G, Curl, GR, Harris, L, Thoracic Outlet Syndrome in Children and Young Adults. Eur J Vasc & Endovasc Surg, 2009; 38:560-564. 7. Noor, S, Curl, GR, Meyers, S, RN, Reduction of Surgeries Secondary to Arterial Site Complications: A Single-Center Experience with an Extra- Vascular Closure Device. Vasc & Endovascular Surgery, 5/18/2010. Articles: Refereed Journals 1. Neefe, J, Curl, GR, Woody, JN: Absolute requirement of adherent cells in the production of adherents cells in the production of human interleukin 2 (IL – 2). Cellular Immunology 63 (1): 71 – 80, 1981. 2. Bush, HL, Nabseth, DC, Curl, GR, O’Hara, ET, Johnson, WC, Vollman, RW: In situ saphenous vein bypass grafts for limb salvage-current fad or viable 7 Alternative to reversed vein bypass grafts. Am. J. Surg. 149:477-480, 1985. 3. Bush, HL, Jakubowski,
Load more

Recommended publications
  • FDA-Approved Pre-Mixed Bag of Ibuprofen
    Corporate Presentation Nasdaq CPIX Safe Harbor Statement This presentation contains forward-looking statements Important factors that could cause actual results to differ concerning our approved products and product materially from those indicated by such forward-looking development, our technology, our competitors, our statements include, among others, those set forth under intellectual property, our financial condition and our plans the headings "Risk factors" and "Management's discussion for research and development programs that involve risks, and analysis of financial condition and results of uncertainties and assumptions. These statements are operations" in our Form 10-K and Form 10-Q Reports on based on the current estimates and assumptions of the file with the SEC. The Company does not undertake any management of Cumberland Pharmaceuticals as of the obligation to release publicly any revisions to these date of this presentation and are subject to uncertainty and forward-looking statements to reflect events or changes in circumstances. Given these uncertainties, you circumstances after the date hereof or to reflect the should not place undue reliance upon these forward- occurrence of unanticipated events. All statements looking statements. Such forward-looking statements are contained in this presentation are made only as of the date subject to risks, uncertainties, assumptions and other of this presentation. For more information on our brands, factors that may cause the actual results of Cumberland including full prescribing and
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al
    US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun.
    [Show full text]
  • Effect of Prostanoids on Human Platelet Function: an Overview
    International Journal of Molecular Sciences Review Effect of Prostanoids on Human Platelet Function: An Overview Steffen Braune, Jan-Heiner Küpper and Friedrich Jung * Institute of Biotechnology, Molecular Cell Biology, Brandenburg University of Technology, 01968 Senftenberg, Germany; steff[email protected] (S.B.); [email protected] (J.-H.K.) * Correspondence: [email protected] Received: 23 October 2020; Accepted: 23 November 2020; Published: 27 November 2020 Abstract: Prostanoids are bioactive lipid mediators and take part in many physiological and pathophysiological processes in practically every organ, tissue and cell, including the vascular, renal, gastrointestinal and reproductive systems. In this review, we focus on their influence on platelets, which are key elements in thrombosis and hemostasis. The function of platelets is influenced by mediators in the blood and the vascular wall. Activated platelets aggregate and release bioactive substances, thereby activating further neighbored platelets, which finally can lead to the formation of thrombi. Prostanoids regulate the function of blood platelets by both activating or inhibiting and so are involved in hemostasis. Each prostanoid has a unique activity profile and, thus, a specific profile of action. This article reviews the effects of the following prostanoids: prostaglandin-D2 (PGD2), prostaglandin-E1, -E2 and E3 (PGE1, PGE2, PGE3), prostaglandin F2α (PGF2α), prostacyclin (PGI2) and thromboxane-A2 (TXA2) on platelet activation and aggregation via their respective receptors. Keywords: prostacyclin; thromboxane; prostaglandin; platelets 1. Introduction Hemostasis is a complex process that requires the interplay of multiple physiological pathways. Cellular and molecular mechanisms interact to stop bleedings of injured blood vessels or to seal denuded sub-endothelium with localized clot formation (Figure1).
    [Show full text]
  • Evaluation of the Allometric Exponents in Prediction of Human Drug Clearance
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2014 Evaluation of the Allometric Exponents in Prediction of Human Drug Clearance Da Zhang Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Other Pharmacy and Pharmaceutical Sciences Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/3533 This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. ©Da Zhang, 2014 All Rights Reserve EVALUATION OF THE ALLOMETRIC EXPONENTS IN PREDICTION OF HUMAN DRUG CLEARANCE A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at Virginia Commonwealth University By Da Zhang Master of Science, University of Arizona, 2004 Director: F. Douglas Boudinot, Ph.D. Professor, School of Pharmacy, VCU Virginia Commonwealth University Richmond, Virginia August, 2014 ACKNOWLEDGEMENTS First and foremost, I would like to sincerely thank my advisor, Dr. F. Douglas Boudinot, for giving me the opportunity to pursue graduate studies under his guidance and for his continuous professional support, guidance, encouragement and patience throughout my graduate program. He was always delighted in sharing his vast knowledge and kind warmth. I would also like to thank Dr. Ahmad for his scientific advice and support through the complet ion of my degree. He has been a kind and helpful mentor for me. I would like to acknowledge my graduate committee members, Drs.
    [Show full text]
  • Update on the Management of Aspirin- Exacerbated Respiratory Disease
    Update on the Management of Aspirin- Exacerbated Respiratory Disease The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Buchheit, Kathleen M., and Tanya M. Laidlaw. 2016. “Update on the Management of Aspirin-Exacerbated Respiratory Disease.” Allergy, Asthma & Immunology Research 8 (4): 298-304. doi:10.4168/ aair.2016.8.4.298. http://dx.doi.org/10.4168/aair.2016.8.4.298. Published Version doi:10.4168/aair.2016.8.4.298 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:27822132 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Review Allergy Asthma Immunol Res. 2016 July;8(4):298-304. http://dx.doi.org/10.4168/aair.2016.8.4.298 pISSN 2092-7355 • eISSN 2092-7363 Update on the Management of Aspirin-Exacerbated Respiratory Disease Kathleen M. Buchheit,1,2* Tanya M. Laidlaw1,2 1Department of Medicine, Harvard Medical School, Boston, MA, USA 2Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, Boston, MA, USA This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Aspirin-exacerbated respiratory disease (AERD) is an adult-onset upper and lower airway disease consisting of eosinophilic nasal polyps, asthma, and respiratory reactions to cyclooxygenase 1 (COX-1) inhibitors.
    [Show full text]
  • 2018 Medicines in Development for Skin Diseases
    2018 Medicines in Development for Skin Diseases Acne Drug Name Sponsor Indication Development Phase ADPS topical Taro Pharmaceuticals USA acne vulgaris Phase II completed Hawthorne, NY www.taro.com AOB101 AOBiome acne vulgaris Phase II (topical ammonia oxidizing bacteria) Cambridge, MA www.aobiome.com ASC-J9 AndroScience acne vulgaris Phase II (androgen receptor degradation Solana Beach, CA www.androscience.com enhancer) BLI1100 Braintree Laboratories acne vulgaris Phase II completed Braintree, MA www.braintreelabs.com BPX-01 BioPharmX acne vulgaris Phase II (minocycline topical) Menlo Park, CA www.biopharmx.com BTX1503 Botanix Pharmaceuticals moderate to severe acne vulgaris Phase II (cannabidiol) Plymouth Meeting, PA www.botanixpharma.com CJM112 Novartis Pharmaceuticals acne vulgaris Phase II (IL-17A protein inhibitor) East Hanover, NJ www.novartis.com clascoterone Cassiopea acne vulgaris Phase III (androgen receptor antagonist) Lainate, Italy www.cassiopea.com Medicines in Development: Skin Diseases ǀ 2018 Update 1 Acne Drug Name Sponsor Indication Development Phase CLS001 Cutanea acne vulgaris Phase II (omiganan) Wayne, PA www.cutanea.com DFD-03 Promius Pharma acne vulgaris Phase III (tazarotene topical) Princeton, NJ www.promiuspharma.com DMT310 Dermata Therapeutics moderate to severe acne vulgaris Phase II (freshwater sponge-derived) San Diego, CA www.dermatarx.com finasteride Elorac severe nodulocystic acne Phase II (cholestenone 5-alpha Vernon Hills, IL www.eloracpharma.com reductase inhibitor) FMX101 Foamix moderate to severe
    [Show full text]
  • The Role of Constrictor Prostanoids in the Development Of
    THE ROLE OF CONSTRICTOR PROSTANOIDS IN THE DEVELOPMENT OF AORTIC COARCTATION-INDUCED HYPERTENSION IN MALE AND FEMALE RATS A Dissertation by WENDY IRENE BALTZER Submitted to the Office of Graduate Studies of Texas A&M University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY December 2003 Major Subject: Veterinary Physiology THE ROLE OF CONSTRICTOR PROSTANOIDS IN THE DEVELOPMENT OF AORTIC COARCTATION-INDUCED HYPERTENSION IN MALE AND FEMALE RATS A Dissertation by WENDY IRENE BALTZER Submitted to Texas A&M University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Approved as to style and content by: _________________________________ _____________________________ John N. Stallone Theresa W. Fossum (Co-Chair of Committee) (Co-Chair of Committee) _______________________________ ___________________________ Jay D. Humphrey David M. Hood (Member) (Member) _______________________________ Glen Laine (Head of Department) December 2003 Major Subject: Veterinary Physiology iii ABSTRACT The Role of Constrictor Prostanoids in the Development of Aortic Coarctation-Induced Hypertension in Male and Female Rats. (December 2003) Wendy Irene Baltzer, B. S., University of California Davis; D.V.M., University of California Davis Co-Chairs of Advisory Committee: Dr. John N. Stallone Dr. Theresa W. Fossum Vascular reactivity to vasopressin and phenylephrine is potentiated by constrictor prostanoids (CP) in normotensive female (F) but not male (M) rat aorta and CP function is estrogen-dependent. This study investigated the effects of estrogen on CP function and arterial blood pressure (MAP) during development of aortic coarctation-induced hypertension (HT). M and F rats, (15-18 wks.) in four groups: normotensive (NT), hypertensive (HT), ovariectomized (OVX), and OVX estrogen-replaced (OE), underwent abdominal aortic coarctation or sham surgery (NT).
    [Show full text]
  • Providing for Duty-Free Treatment for Specified Pharmaceutical Active
    13 . 3 . 97 I EN I Official Journal of the European Communities No L 71 / 1 I (Acts whose publication is obligatory) COUNCIL REGULATION (EC) No 467/97 of 3 March 1997 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an 'international non-proprietary name' (INN) from the World Health Organization and specified products used for the manufacture of finished pharmaceuticals and withdrawing duty-free treatment as pharmaceutical products from certain INNs whose predominant use is not pharmaceutical THE COUNCIL OF THE EUROPEAN UNION , whereas in the context of the review it was concluded that it was appropriate to rectify the situation with regard Having regard to the Treaty establishing the European to certain INNs whose use was predominantly non­ Community, and in particular Article 113 thereof, pharmaceutical and which had been inadvertently included among those INNs already receiving duty-free treatment, Having regard to the proposal from the Commission , Whereas, in the course of the Uruguay Round negotia­ HAS ADOPTED THIS REGULATION : tions the Community and a number of countries discussed duty-free treatment of pharmaceutical products ; Article 1 Whereas the participants in those discussions concluded that in addition to products falling within the Harm­ From 1 April 1997 the Community shall also accord onized System (HS) Chapter 30 and HS headings 2936 , duty-free treatment for the INNs listed in Annex I as well 2937, 2939 and 2941 , duty-free treatment should be given as the salts, esters and hydrates of such products . to designated pharmaceutical active ingredients bearing an 'international non-proprietary name' (INN) from the Article 2 World Health Organization as well as specified salts , esters and hydrates of such INNs, and also to designated From 1 April 1997 the Community shall also grant duty­ products used for the production and manufacture of free treatment for the products used in the production finished products ; and manufacture of pharmaceutical products listed in Annex II .
    [Show full text]
  • 2019 BWH AERD Newsletter
    The Summer 2019 Newsletter at Brigham and Women’s Hospital Information for patients with aspirin-exacerbated respiratory disease (AERD) / Samter’s Triad MESSAGE FROM OUR DIRECTORS What’s Inside In part due to our education and outreach efforts, more and more centers across the United States are developing Message from our Directors (page 1) proficiency in AERD and aspirin challenges/desensitizations, which has led to increased availability of healthcare By the Numbers providers with expertise in diagnosis and management of the Enrollment update and information from disease. Indeed there is much hope on the horizon, though our AERD Patient Registry (page 1) still many challenges ahead. With the information we gathered from last year’s Updates to the Treatment of AERD surveys, we were able to learn from all of you, and publish and Nasal Polyps three important papers to help teach others: 1. “Hearing loss and middle ear symptoms in aspirin- ➢ Dupixent has recently been approved as exacerbated respiratory disease”, in which we showed that treatment for Nasal Polyp (page 2) ear complications, eustachian tube dysfunction, and hearing ➢ Findings from Polyp 2 Study - Xolair for loss are common in AERD. Spring 2016 Nasal Polyps (page 2) 2. “A Retrospective Analysis of Esophageal Eosinophilia in Patients with Aspirin-exacerbated RespiratoryNewsletter Disease”, in which we showed that some patients on high-dose aspirin Upcoming and Ongoing Clinical develop eosinophils in their esophagus. Trials 3. “Accidental ingestion of aspirin and nonsteroidal anti- inflammatory drugs is common in patients with aspirin- ➢ Oral medication for nasal polyps— exacerbated respiratory disease”, in which we showed that GB001 (pages 2- 3) about ¼ of patients with AERD had accidentally taken an ➢ Potential treatment for eosinophilic NSAID that caused a reaction.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome Wide Association Study Authors: Thomas A
    Author Manuscript Published OnlineFirst on October 8, 2020; DOI: 10.1158/1535-7163.MCT-19-1106 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Repurposing of a thromboxane receptor inhibitor based on a novel role in metastasis identified by Phenome Wide Association Study Authors: Thomas A. Werfel1, 7, Donna J. Hicks1, Bushra Rahman1, Wendy E. Bendeman1, Matthew T. Duvernay2, Jae G. Maeng2, Heidi Hamm2, Robert R. Lavieri3, Meghan M. Joly3, Jill M. Pulley3, David L. Elion4, Dana M. Brantley-Sieders5,6, Rebecca S. Cook1, 4, 5, 8* Affiliations: 1Department of Cell & Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN 37232 USA 2Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232 USA 3Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN 37232 USA 4Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN 37232 USA 5Breast Cancer Research Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232 USA 6Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232 7Department of Chemical Engineering, University of Mississippi, University, MS 38677 USA 8Department of Biomedical Engineering, Vanderbilt University School of Engineering, Nashville, TN 37232 USA *To whom correspondence should be addressed: Rebecca S. Cook, Ph.D. 759 Preston Research Building Vanderbilt University 2220 Pierce Avenue Nashville, TN 37232 Email: [email protected] Office phone: 615-936-3813 Conflict of Interest: CPI211 used in this study was provided by Cumberland Pharmaceuticals, Inc. (CPI). CPI had no role in study design, experimental conduct, data collection and analysis, or preparation of the manuscript.
    [Show full text]
  • Reproductive Health Guideline Appendix 3 – Search Strategies
    SUPPLEMENTARY APPENDIX 3: Search Strategies 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases All searches initially run on 11/8/2017 and updated on 5/8/2018. Searches run from database inception to 5/8/2018. PUBMED Syntax Guide for PubMed [MeSH] = Medical Subject Heading [Text Word] = Includes all words and numbers in the title, abstract, other abstract, MeSH terms, MeSH Subheadings, Publication Types, Substance Names, Personal Name as Subject, Corporate Author, Secondary Source, Comment/Correction Notes, and Other Terms - typically non-MeSH subject terms (keywords)…assigned by an organization other than NLM [MeSH subheading] = a Medical Subject [Title/Abstract] = Includes words in the title Heading subheading, e.g.
    [Show full text]